Cipher Pharmaceuticals Inc. (TSX:CPH)
Canada
· Delayed Price · Currency is CAD | Market Cap | 469.99M |
| Revenue (ttm) | 69.17M |
| Net Income (ttm) | 37.47M |
| Shares Out | 25.39M |
| EPS (ttm) | 1.44 |
| PE Ratio | 12.86 |
| Forward PE | 18.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,760 |
| Average Volume | 26,759 |
| Open | 18.49 |
| Previous Close | 18.51 |
| Day's Range | 18.15 - 18.56 |
| 52-Week Range | 11.87 - 19.63 |
| Beta | 0.52 |
| RSI | 53.16 |
| Earnings Date | May 7, 2026 |
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the manage... [Read more]
Full Company ProfileFinancial Performance
In 2025, Cipher Pharmaceuticals's revenue was $50.45 million, an increase of 51.22% compared to the previous year's $33.36 million. Earnings were $27.33 million, an increase of 136.72%.
Financial numbers in USD Financial StatementsNews
CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)
WASHINGTON--(BUSINESS WIRE)-- #DTP--CaryHealth, a leading digital health company, today announced the launch of its direct-to-patient (DTP) platform to support seamless access to Natroba (spinosad), a...
Cipher Pharmaceuticals Earnings Call Transcript: Q4 2025
Revenue and earnings more than doubled in 2025, driven by Natroba's strong US performance and a stable Canadian base. The new DTC platform and upcoming Canadian launch are expected to fuel further growth, while licensing revenue faces pressure from generics.
Cipher Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue and profit growth, led by Natroba, with significant debt reduction and robust free cash flow. Licensing revenue declined due to generic competition, but new DTC and global expansion strategies are underway. Several state Medicaid bids for Natroba are pending.
Cipher Pharmaceuticals Earnings Call Transcript: Q2 2025
Record Q2 2025 net revenue and EBITDA were driven by strong NATROBA sales and growth in the Canadian portfolio. Significant deleveraging and capital returns were achieved, while U.S. licensing revenue declined due to generic competition.
Cipher Pharmaceuticals Earnings Call Transcript: Q1 2025
Q1 2025 saw a 105% revenue increase to $12M, driven by Natroba's strong U.S. launch and robust Canadian sales. Licensing revenue declined due to generics, but adjusted EBITDA rose 73%. Natroba's Medicaid win in Illinois and a $15M debt repayment post-quarter highlight key developments.
Cipher Pharmaceuticals Earnings Call Transcript: Q4 2024
Revenue and earnings surged in 2024, driven by the Natroba acquisition and strong Epuris growth, despite lower U.S. licensing revenue. Direct commercialization of Natroba and global expansion efforts are expected to fuel further growth, with robust cash flow supporting share repurchases.
Cipher Pharmaceuticals Earnings Call Transcript: Q3 2024
Q3 revenue surged 71% year-over-year, driven by the Natroba acquisition, while gross margin rose to 79%. Integration and transition costs impacted earnings, but normalization and further growth are expected in 2025 as the company pursues additional product acquisitions and licensing deals.
Cipher Pharmaceuticals Transcript: Planet MicroCap Showcase: VANCOUVER 2024
Cipher's acquisition of Natroba has doubled sales and EBITDA, with strong growth expected from U.S. market share gains and international expansion. The company is optimizing its sales force, exploring new product launches, and maintains a disciplined financial position.
Cipher Pharmaceuticals Earnings Call Transcript: Q2 2024
Q2 2024 saw stable legacy business performance and the transformative acquisition of Natroba, expected to drive significant growth in the U.S. and globally. MOB-015 achieved market leadership in Sweden and is set for Canadian launch in 2026.
Cipher Pharmaceuticals Earnings Call Transcript: Q1 2024
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mississauga, Ontario--(Newsfile Corp. - April 3, 2024) - Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which wil...